Eli Lilly's May 21, 2026 announcement reported mean body-weight reduction of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg, compared with 2.2% on placebo [1][2]
In clinical trials, some participants do not reach their assigned dose due to side effects or other factors
It is designed for people who are getting on well with the standard 2.4mg injection, but have found their weight loss has stopped
Blood pressure, blood glucose, HbA1c, lipid panels
Trials with older GLP-1 drugs (liraglutide, exenatide) including the large ADJUNCT ONE and ADJUNCT TWO studies showed modest HbA1c improvements of 0.10.7%, meaningful weight loss, and lower insulin requirements, but also raised early concerns about hypoglycemia and ketosis that kept enthusiasm in check for years
Semaglutide binds to albumin (a protein in the blood), which protects it from rapid degradation and extends its presence in the circulation